Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Substance Abuse, Intravenous"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 1309
Tytuł:
Improving access to HIV care among people who inject drugs through tele-harm reduction: a qualitative analysis of perceived discrimination and stigma.
Autorzy:
Scaramutti C; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA. .
Hervera B; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Rivera Y; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Chueng TA; 2Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Forrest DW; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Suarez E Jr; Department of Psychiatry and Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Serota DP; 2Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Alkamli H; Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Ciraldo K; Department of Family and Community Medicine & Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Bartholomew TS; Division of Health Services Research and Policy, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA.
Tookes HE; 2Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2024 Feb 23; Vol. 21 (1), pp. 50. Date of Electronic Publication: 2024 Feb 23.
Typ publikacji:
Journal Article
MeSH Terms:
Substance Abuse, Intravenous*/complications
Substance Abuse, Intravenous*/therapy
Drug Users*
HIV Infections*/complications
HIV Infections*/therapy
Humans ; Health Services Accessibility ; Harm Reduction ; Perceived Discrimination
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Delivering integrated strategies from a mobile unit to address the intertwining epidemics of HIV and addiction in people who inject drugs: the HPTN 094 randomized controlled trial protocol (the INTEGRA Study).
Autorzy:
Goodman-Meza D; Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles, 10833 Le Conte Ave., CHS 52-215, Los Angeles, CA, 90095-1688, USA. .
Shoptaw S; Department of Family Medicine, University of California, Los Angeles, Los Angeles, CA, USA.
Hanscom B; Statistical Center for HIV/AIDS Research and Prevention (SCHARP), Seattle, WA, USA.
Smith LR; Division of Infectious Diseases and Global Public Health, University of California, San Diego, San Diego, CA, USA.
Andrew P; Family Health International (FHI 360), Durham, NC, USA.
Kuo I; Milken Institute School of Public Health Department of Epidemiology, George Washington University, Washington, DC, USA.
Lake JE; UTHealth-Houston, Houston, TX, USA.
Metzger D; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Morrison EAB; ICAP, Mailman School of Public Health, Columbia University, New York, NY, USA.
Cummings M; Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Fogel JM; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Richardson P; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Harris J; Family Health International (FHI 360), Durham, NC, USA.
Heitner J; Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.
Stansfield S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
El-Bassel N; School of Social Work, Columbia University, New York, NY, USA.
Pokaż więcej
Corporate Authors:
HPTN 094 Study Team
Źródło:
Trials [Trials] 2024 Feb 15; Vol. 25 (1), pp. 124. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Substance Abuse, Intravenous*/epidemiology
Substance Abuse, Intravenous*/complications
Drug Users*
HIV Infections*/diagnosis
HIV Infections*/epidemiology
HIV Infections*/prevention & control
Sexually Transmitted Diseases*/diagnosis
Sexually Transmitted Diseases*/epidemiology
Sexually Transmitted Diseases*/prevention & control
Opioid-Related Disorders*/diagnosis
Opioid-Related Disorders*/epidemiology
Opioid-Related Disorders*/prevention & control
Humans ; Pharmaceutical Preparations ; Randomized Controlled Trials as Topic
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.
Autorzy:
McKellar MS; Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, P.O. Box 102359, Durham, NC, 27710, USA. .
Des Marais AC; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Chen H; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Choi Y; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Lilly R; North Carolina Harm Reduction Coalition, Wilmington, NC, USA.; Port City Harm Reduction, Wilmington, NC, USA.
Ayers D; Queen City Harm Reduction, Charlotte, NC, USA.
Bennett J; North Carolina Harm Reduction Coalition, Wilmington, NC, USA.
Kestner L; Queen City Harm Reduction, Charlotte, NC, USA.
Perry B; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Poley S; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Corneli A; Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine, P.O. Box 102359, Durham, NC, 27710, USA.; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Meade CS; Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA.; Wake Forest University, Winston-Salem, NC, USA.
Sachdeva N; Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.; North Carolina Association of County Commissioners, Raleigh, NC, USA.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2024 Mar 26; Vol. 21 (1), pp. 69. Date of Electronic Publication: 2024 Mar 26.
Typ publikacji:
Clinical Trial; Journal Article
MeSH Terms:
Anti-HIV Agents*/therapeutic use
HIV Infections*/prevention & control
Opioid-Related Disorders*/drug therapy
Pre-Exposure Prophylaxis*
Substance Abuse, Intravenous*/drug therapy
Humans ; Male ; Buprenorphine, Naloxone Drug Combination/therapeutic use ; Pilot Projects ; Female
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Acceptance and feasibility of a low-threshold and substitution services-based periodical monitoring system for blood-borne and sexually transmitted infections among people who inject drugs in Germany: a mixed-methods analysis.
Autorzy:
Krings A; Department of Infectious Disease Epidemiology, Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany. .
Steffen G; Department of Infectious Disease Epidemiology, Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany.
Zimmermann R; Department of Infectious Disease Epidemiology, Robert Koch Institute, Nordufer 20, 13353, Berlin, Germany.
Pokaż więcej
Corporate Authors:
DRUCK 2.0-study group
Źródło:
Harm reduction journal [Harm Reduct J] 2024 Mar 14; Vol. 21 (1), pp. 62. Date of Electronic Publication: 2024 Mar 14.
Typ publikacji:
Journal Article
MeSH Terms:
Substance Abuse, Intravenous*/drug therapy
Drug Users*
Sexually Transmitted Diseases*
HIV Infections*/prevention & control
Hepatitis C*/epidemiology
Humans ; Feasibility Studies ; Pilot Projects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Come back when you're infected: pharmacy access to sterile syringes in an Arizona Secret Shopper Study, 2023.
Autorzy:
Russell DM; Arizona State University, Tempe, AZ, USA.; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; Drug Policy Research and Advocacy Board (DPRAB), University of Arizona, Tucson, AZ, USA.
Meyerson BE; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA. .; Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA. .; Center for Comprehensive Pain and Addiction, University of Arizona Health Sciences, Tucson, AZ, USA. .
Mahoney AN; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; Southwest Recovery Alliance, Phoenix, AZ, USA.; Drug Policy Research and Advocacy Board (DPRAB), University of Arizona, Tucson, AZ, USA.
Garnett I; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; Drug Policy Research and Advocacy Board (DPRAB), University of Arizona, Tucson, AZ, USA.; Center for Comprehensive Pain and Addiction, University of Arizona Health Sciences, Tucson, AZ, USA.
Ferrell C; Drug Policy Research and Advocacy Board (DPRAB), University of Arizona, Tucson, AZ, USA.; CAN Community Health, Phoenix, AZ, USA.
Newgass K; Southwest Recovery Alliance, Phoenix, AZ, USA.; Drug Policy Research and Advocacy Board (DPRAB), University of Arizona, Tucson, AZ, USA.
Agley JD; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; Indiana University School of Public Health-Bloomington, Bloomington, IN, USA.
Crosby RA; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; University of Kentucky College of Public Health, Lexington, KY, USA.
Bentele KG; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; Southwest Institute for Research On Women, University of Arizona, Tucson, AZ, USA.
Vadiei N; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; College of Pharmacy, University of Arizona, Tucson, AZ, USA.
Frank D; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; School of Global Public Health, New York University, New York, USA.
Linde-Krieger LB; Harm Reduction Research Lab, University of Arizona College of Medicine-Tucson, Tucson, AZ, USA.; Family and Community Medicine, College of Medicine, University of Arizona, Tucson, AZ, USA.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2024 Feb 22; Vol. 21 (1), pp. 49. Date of Electronic Publication: 2024 Feb 22.
Typ publikacji:
Journal Article
MeSH Terms:
Pharmacies*
HIV Infections*/prevention & control
Substance Abuse, Intravenous*
Pharmacy*
Humans ; Syringes ; Arizona
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge.
Autorzy:
Bromberg DJ; Yale School of Public Health, Yale University, New Haven, Connecticut, USA.; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, Connecticut, USA.; Yale School of Medicine, Yale University, New Haven, Connecticut, USA.
Machavariani E; Yale School of Medicine, Yale University, New Haven, Connecticut, USA.
Madden LM; Yale School of Medicine, Yale University, New Haven, Connecticut, USA.; APT Foundation, New Haven, Connecticut, USA.
Dumchev K; Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.
LaMonaca K; Yale School of Medicine, Yale University, New Haven, Connecticut, USA.
Earnshaw VA; University of Delaware, Newark, Delaware, USA.
Pykalo I; Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.
Filippovych M; Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.
Haddad MS; Center for Key Populations, Community Health Center, Inc., Middletown, Connecticut, USA.
Dvoriak S; Ukrainian Institute on Public Health Policy, Kyiv, Ukraine.
Altice FL; Yale School of Public Health, Yale University, New Haven, Connecticut, USA.; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, Connecticut, USA.; Yale School of Medicine, Yale University, New Haven, Connecticut, USA.; University of Delaware, Newark, Delaware, USA.
Pokaż więcej
Źródło:
Journal of the International AIDS Society [J Int AIDS Soc] 2024 Feb; Vol. 27 (2), pp. e26202.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Substance Abuse, Intravenous*/complications
HIV Infections*/drug therapy
HIV Infections*/prevention & control
HIV Infections*/complications
Humans ; Methadone/therapeutic use ; Analgesics, Opioid/therapeutic use ; Ukraine ; Primary Health Care
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Drug preparation, injection-related infections, and harm reduction practices among a national sample of individuals entering treatment for opioid use disorder.
Autorzy:
Marks LR; Division of Infectious Disease, Washington University School of Medicine, Campus Box 8051, 4523 Clayton Avenue, St. Louis, MO, USA. .
Durkin MJ; Division of Infectious Disease, Washington University School of Medicine, Campus Box 8051, 4523 Clayton Avenue, St. Louis, MO, USA.
Ayres K; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Ellis M; Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2024 Jan 19; Vol. 21 (1), pp. 16. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:
Journal Article
MeSH Terms:
Substance Abuse, Intravenous*/complications
Substance Abuse, Intravenous*/epidemiology
Opioid-Related Disorders*/epidemiology
Opioid-Related Disorders*/complications
HIV Infections*/complications
Humans ; Needle-Exchange Programs ; Harm Reduction ; Abscess ; Drug Compounding
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
People Who Inject Drugs in Mozambique: We need to normalize HIV treatment and care services in specialized community centers for people who inject drugs!
Autorzy:
Semá Baltazar C; National Institute of Health, P.O. Box 264, Maputo, Mozambique. .
Ribeiro Banze A; National Institute of Health, P.O. Box 264, Maputo, Mozambique.
Seleme J; Mozambique National Program for STI, HIV and AIDS Control, Ministry Oh Health, Maputo, Mozambique.
Boothe M; UNAIDS, Maputo, Mozambique.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2024 Jan 06; Vol. 21 (1), pp. 6. Date of Electronic Publication: 2024 Jan 06.
Typ publikacji:
Letter
MeSH Terms:
Drug Users*
Substance Abuse, Intravenous*/complications
Substance Abuse, Intravenous*/epidemiology
Substance Abuse, Intravenous*/therapy
Epidemics*
HIV Infections*/drug therapy
HIV Infections*/epidemiology
Humans ; Mozambique
Opinia redakcyjna
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Injection cessation and relapse to injection and the associated factors among people who inject drugs in Iran: The Rostam study.
Autorzy:
Mehmandoost S; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Mirzazadeh A; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Karamouzian M; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.; Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Khezri M; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.; Department of Epidemiology, New York University School of Global Public Health, New York, NY, USA.
Sharafi H; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.; Research Centre, Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.; Department of Psychiatry and Addictology, Faculty of Medicine, Université de Montréal, Montréal, QC, Canada.
Shahesmaeili A; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Maghsoudi SH; Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Ghalekhani N; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Tavakoli F; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Bazrafshani MS; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Shokoohi M; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Aghaali N; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Haghdoost AA; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Sharifi H; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. .
Pokaż więcej
Źródło:
Substance abuse treatment, prevention, and policy [Subst Abuse Treat Prev Policy] 2023 Nov 29; Vol. 18 (1), pp. 72. Date of Electronic Publication: 2023 Nov 29.
Typ publikacji:
Journal Article
MeSH Terms:
HIV Infections*/complications
Substance Abuse, Intravenous*/epidemiology
Substance Abuse, Intravenous*/complications
Drug Users*
Hepatitis C*/epidemiology
Hepatitis C*/complications
Humans ; Female ; Iran/epidemiology ; Cohort Studies ; Hepacivirus ; Recurrence ; Prevalence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of a social network intervention on HIV seroconversion among people who inject drugs in Ukraine: moderation by network gender composition.
Autorzy:
Wiginton JM; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, USA.; School of Social Work, San Diego State University, 5500 Campanile Dr, San Diego, CA, 92182, USA.
Booth R; Department of Psychiatry, University of Colorado School of Medicine, Denver, USA.
Smith LR; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, USA.
Shakya S; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, USA.
da Silva CE; Herbert Wertheim School of Public Health & Human Longevity Science, University of California San Diego, San Diego, USA.; School of Public Health, San Diego State University, San Diego, USA.
Patterson TL; Departments of Psychiatry, University of California San Diego, San Diego, USA.
Pitpitan EV; Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, USA. .; School of Social Work, San Diego State University, 5500 Campanile Dr, San Diego, CA, 92182, USA. .
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2023 Nov 08; Vol. 20 (1), pp. 165. Date of Electronic Publication: 2023 Nov 08.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
HIV Seropositivity*/complications
HIV Infections*/epidemiology
HIV Infections*/prevention & control
HIV Infections*/complications
Drug Users*
Substance Abuse, Intravenous*/epidemiology
Substance Abuse, Intravenous*/complications
Male ; Humans ; Female ; Ukraine/epidemiology ; Social Networking
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Willingness to use and distribute HIV self-testing kits among people who inject drugs in the San Diego-Tijuana border region.
Autorzy:
Pines HA; Division of Epidemiology and Biostatistics, School of Public Health, San Diego State University, San Diego, CA, USA. .; Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA. .; Department of Medicine, University of California, San Diego, La Jolla, CA, USA. .
Eger WH; Department of Medicine, University of California, San Diego, La Jolla, CA, USA.; School of Social Work, San Diego State University, San Diego, CA, USA.
Skaathun B; Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Vera CF; Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Harvey-Vera A; Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Rangel G; Mexico Section of the US-Mexico Border Health Commission, Tijuana, Baja California, Mexico.; El Colegio de la Frontera Norte, Tijuana, Baja California, Mexico.
Strathdee SA; Department of Medicine, University of California, San Diego, La Jolla, CA, USA.
Bazzi AR; Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, CA, USA.; School of Public Health, Boston University, Boston, MA, USA.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2024 Jan 03; Vol. 21 (1), pp. 4. Date of Electronic Publication: 2024 Jan 03.
Typ publikacji:
Journal Article
MeSH Terms:
Substance Abuse, Intravenous*/epidemiology
HIV Infections*/diagnosis
HIV Infections*/epidemiology
Drug Users*
Humans ; Self-Testing ; Surveys and Questionnaires
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Phylogenetic Analysis of Hepatitis C Virus Infections in a Large Belgian Cohort Using Next-Generation Sequencing of Full-Length Genomes.
Autorzy:
Christensen KT; Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Pierard F; Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Bonsall D; Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LF, UK.; The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
Bowden R; The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
Barnes E; Peter Medawar Building for Pathogen Research, University of Oxford, Oxford OX1 3SY, UK.; Translational Gastroenterology Unit, University of Oxford, Oxford OX3 9DU, UK.; Oxford NIHR Biomedical Research Centre, University of Oxford, Oxford OX3 9DU, UK.
Florence E; Department of General Internal Medicine, Infectious Diseases and Tropical Medicine, Antwerp University Hospital, 2650 Edegem, Belgium.; Department of Clinical Sciences, Institute of Tropical Medicine, 2000 Antwerp, Belgium.
Ansari MA; Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Nguyen D; The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
de Cesare M; The Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, UK.
Nevens F; Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.
Robaeys G; Department of Gastroenterology and Hepatology, University Hospitals Leuven, 3000 Leuven, Belgium.; Faculty of Medicine and Life Sciences-LCRC, UHasselt, Agoralaan, 3590 Diepenbeek, Belgium.; Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, 3600 Genk, Belgium.
Schrooten Y; Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.; Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium.
Busschots D; Faculty of Medicine and Life Sciences-LCRC, UHasselt, Agoralaan, 3590 Diepenbeek, Belgium.; Department of Gastroenterology and Hepatology, Ziekenhuis Oost-Limburg, 3600 Genk, Belgium.
Simmonds P; Henry Wellcome Building for Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Old Road Campus, Headington, Oxford OX3 7BN, UK.
Vandamme AM; Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.; Global Health and Tropical Medicine, Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Rua da Junqueira 100, 1349-008 Lisbon, Portugal.
Van Wijngaerden E; Department of General Internal Medicine, University Hospitals Leuven, 3000 Leuven, Belgium.
Dierckx T; Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.
Cuypers L; Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.; Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium.; Laboratory of Clinical Microbiology, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.
Van Laethem K; Laboratory of Clinical and Epidemiological Virology, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, KU Leuven, 3000 Leuven, Belgium.; Department of Laboratory Medicine, University Hospitals Leuven, 3000 Leuven, Belgium.
Pokaż więcej
Źródło:
Viruses [Viruses] 2023 Dec 08; Vol. 15 (12). Date of Electronic Publication: 2023 Dec 08.
Typ publikacji:
Journal Article
MeSH Terms:
Substance Abuse, Intravenous*/complications
HIV Infections*
Sexual and Gender Minorities*
Hepatitis C*
HIV Seropositivity*
Male ; Humans ; Hepacivirus/genetics ; Phylogeny ; Homosexuality, Male ; Belgium/epidemiology ; High-Throughput Nucleotide Sequencing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prevalence and correlates of violence among sexual and injecting partners of people who inject drugs living with HIV in Kenya: a cross-sectional study.
Autorzy:
Aung SWKH; University of Washington, Seattle, WA, USA. .
Kingston H; University of Washington, Seattle, WA, USA.
Mbogo LW; University of Washington Global Assistance Program-Kenya, Nairobi, Kenya.
Sambai B; University of Washington Global Assistance Program-Kenya, Nairobi, Kenya.
Monroe-Wise A; University of Washington, Seattle, WA, USA.
Ludwig-Barron NT; University of Washington, Seattle, WA, USA.
Bukusi D; Kenyatta National Hospital, Nairobi, Kenya.
Sinkele W; Support for Addiction Prevention and Treatment in Africa (SAPTA), Nairobi, Kenya.
Gitau E; Support for Addiction Prevention and Treatment in Africa (SAPTA), Nairobi, Kenya.
Masyuko S; University of Washington, Seattle, WA, USA.; National AIDS and STI Control Programme (NASCOP), Kenya Ministry of Health, Nairobi, Kenya.
Herbeck JT; University of Washington, Seattle, WA, USA.
Farquhar C; University of Washington, Seattle, WA, USA.
Guthrie BL; University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2023 Nov 02; Vol. 20 (1), pp. 164. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Substance Abuse, Intravenous*/epidemiology
Drug Users*
HIV Infections*/epidemiology
Male ; Humans ; Female ; Cross-Sectional Studies ; Prevalence ; Kenya/epidemiology ; Prospective Studies ; Violence ; Sexual Partners
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A descriptive study of hepatitis C in people who inject drugs.
Autorzy:
Shivaprakash P; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Patel V; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.; National Drug Dependence Treatment Centre, All India Institute of Medical Sciences, New Delhi, India.
Shadakshari D; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Verma R; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Shukla L; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Mahadevan J; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Kandasamy A; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Chand PK; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Benegal V; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Sethuraman L; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Sharma P; Department of Clinical Psychopharmacology & Neurotoxicology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Murthy P; Centre for Addiction Medicine, Department of Psychiatry, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Pokaż więcej
Źródło:
The Indian journal of medical research [Indian J Med Res] 2023 Nov 01; Vol. 158 (5&6), pp. 559-564. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article
MeSH Terms:
Substance Abuse, Intravenous*/epidemiology
HIV Infections*/epidemiology
Drug Users*
Hepatitis C*/epidemiology
Humans ; Hepacivirus ; Seroepidemiologic Studies ; Retrospective Studies ; India/epidemiology ; HIV ; Prevalence
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Population-level prevalence of detectable HIV viremia in people who inject drugs (PWID) in Ukraine: Implications for HIV treatment and case finding interventions.
Autorzy:
Sazonova Y; PEPFAR Coordination Office in Ukraine, Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.
Kulchynska R; Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.
Azarskova M; Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.
Liulchuk M; State Institution 'The L.V. Gromashevskij Institute of Epidemiology and Infectious Diseases of NAMS of Ukraine', Kyiv, Ukraine.
Salyuk T; Monitoring and Evaluation Unit, ICF 'Alliance for Public Health', Kyiv, Ukraine.
Doan I; Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.
Barzilay E; Division of Global HIV and TB, U.S. Centers for Disease Control and Prevention, Kyiv, Ukraine.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Oct 26; Vol. 18 (10), pp. e0290661. Date of Electronic Publication: 2023 Oct 26 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Substance Abuse, Intravenous*/complications
Substance Abuse, Intravenous*/epidemiology
Substance Abuse, Intravenous*/drug therapy
Drug Users*
HIV Infections*/complications
HIV Infections*/drug therapy
HIV Infections*/epidemiology
Middle Aged ; Humans ; Female ; Adult ; Male ; Analgesics, Opioid/therapeutic use ; Ukraine/epidemiology ; Prevalence ; Cross-Sectional Studies ; Viremia/drug therapy ; Viremia/epidemiology ; Viremia/complications
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
HIV risk and prevention among clients of a delivery-based harm reduction service during an HIV outbreak among people who use drugs in northern rural Minnesota, USA.
Autorzy:
Palayew A; Department of Epidemiology, University of Washington, Seattle, WA, USA.
Knudtson K; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, WA, Seattle, USA.
Purchase S; Harm Reduction Sisters, Duluth, MN, USA.
Clark S; Harm Reduction Sisters, Duluth, MN, USA.
Possehl L; Harm Reduction Sisters, Duluth, MN, USA.
Healy E; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, WA, Seattle, USA.
Deutsch S; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, WA, Seattle, USA.
McKnight CA; School of Global Public Health, New York University, New York City, NY, USA.
Des Jarlais D; School of Global Public Health, New York University, New York City, NY, USA.
Glick SN; Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, WA, Seattle, USA. .
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2023 Aug 02; Vol. 20 (1), pp. 102. Date of Electronic Publication: 2023 Aug 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Substance Abuse, Intravenous*/epidemiology
Substance Abuse, Intravenous*/complications
HIV Infections*/epidemiology
HIV Infections*/prevention & control
HIV Infections*/complications
Humans ; Female ; Male ; Pharmaceutical Preparations ; Minnesota/epidemiology ; Harm Reduction ; Cross-Sectional Studies ; Disease Outbreaks/prevention & control
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impacts of COVID-19 on sexual risk behaviors, safe injection practices, and access to HIV services among key populations in Zambia: Findings from a rapid qualitative formative assessment.
Autorzy:
Parmley LE; ICAP at Columbia University, New York, NY, United States of America.
Nkumbula T; ICAP at Columbia University, Lusaka, Zambia.
Chilukutu L; ICAP at Columbia University, Lusaka, Zambia.
Chelu L; ICAP at Columbia University, Lusaka, Zambia.
Mulemfwe C; ICAP at Columbia University, Lusaka, Zambia.
Hanunka B; Division of Global HIV & TB, Center for Global Health, U.S. Centers for Disease Control and Prevention, Lusaka, Zambia.
Mwale J; National HIV/AIDS/STI/TB Council, Lusaka, Zambia.
Neal J; Division of Global HIV & TB, Center for Global Health, U.S. Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
Handema R; Tropical Diseases Research Centre, Ndola, Zambia.
Kasonde P; ICAP at Columbia University, Lusaka, Zambia.
Mutale K; Key Populations Consortium, Lusaka, Zambia.
Sakala HM; Key Populations Consortium, Lusaka, Zambia.
Lahuerta M; ICAP at Columbia University, New York, NY, United States of America.; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Aug 01; Vol. 18 (8), pp. e0289007. Date of Electronic Publication: 2023 Aug 01 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections*/epidemiology
Substance Abuse, Intravenous*/complications
Substance Abuse, Intravenous*/epidemiology
Sexual and Gender Minorities*
COVID-19*/epidemiology
Male ; Humans ; Female ; Homosexuality, Male ; Zambia/epidemiology ; Pandemics ; SARS-CoV-2 ; Risk-Taking
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Houselessness and syringe service program utilization among people who inject drugs in eight rural areas across the USA: a cross-sectional analysis.
Autorzy:
Ballard AM; Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA, 30322, USA. .; School of Public Health, Georgia State University, 140 Decatur Street SE, Atlanta, GA, 30303, USA. .
Falk D; Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA, 30322, USA.
Greenwood H; Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA, 30322, USA.
Gugerty P; Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA, 30322, USA.
Feinberg J; School of Medicine, West Virginia University, Morgantown, WV, USA.
Friedmann PD; Office of Research, University of Massachusetts Chan Medical School-Baystate, Springfield, MA, USA.
Go VF; Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Jenkins WD; School of Medicine, Southern Illinois University, Carbondale, IL, USA.
Korthuis PT; Department of Medicine, Oregon Health & Science University, Portland, OR, USA.
Miller WC; College of Public Health, The Ohio State University, Columbus, OH, USA.
Pho MT; Department of Medicine, University of Chicago, Chicago, IL, USA.
Seal DW; School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA, USA.
Smith GS; School of Medicine, West Virginia University, Morgantown, WV, USA.
Stopka TJ; School of Medicine, Tufts University, Boston, MA, USA.
Westergaard RP; School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
Zule WA; RTI International, Research Triangle Park, NC, USA.
Young AM; College of Public Health, University of Kentucky, 111 Washington Avenue, Lexington, KY, 40536, USA.
Cooper HLF; Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA, 30322, USA.
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2023 Oct 26; Vol. 20 (1), pp. 157. Date of Electronic Publication: 2023 Oct 26.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.; Research Support, Non-U.S. Gov't
MeSH Terms:
Substance Abuse, Intravenous*/epidemiology
Drug Users*
HIV Infections*
Humans ; Needle-Exchange Programs ; Cross-Sectional Studies ; Data Collection
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Awareness and willingness to use HIV self-testing among people who inject drugs in Iran.
Autorzy:
Khezri M; Department of Epidemiology, New York University School of Global Public Health, New York, NY, USA.; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Goldmann E; Department of Epidemiology, New York University School of Global Public Health, New York, NY, USA.; Center for Drug Use and HIV/HCV Research, New York, NY, USA.
Tavakoli F; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Karamouzian M; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.; Centre on Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Shokoohi M; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.; Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada.
Mehmandoost S; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Ghalekhani N; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Haghdoost AA; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Des Jarlais D; Department of Epidemiology, New York University School of Global Public Health, New York, NY, USA.; Center for Drug Use and HIV/HCV Research, New York, NY, USA.
Mirzazadeh A; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Sharifi H; HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran. .
Pokaż więcej
Źródło:
Harm reduction journal [Harm Reduct J] 2023 Oct 07; Vol. 20 (1), pp. 145. Date of Electronic Publication: 2023 Oct 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Substance Abuse, Intravenous*/epidemiology
Drug Users*
HIV Infections*/epidemiology
Humans ; HIV ; Self-Testing ; Iran/epidemiology ; HIV Testing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Estimating prevalence and modelling correlates of HIV test positivity among female sex workers, men who have sex with men, people who inject drugs, transgender people and prison inmates in Sierra Leone, 2021.
Autorzy:
Dwomoh D; Department of Biostatistics, School of Public Health, College of Health Sciences, University of Ghana, Accra, Ghana. .
Wurie I; Health and Education Quality Systems Strengthening, Freetown, Sierra Leone.
Harding Y; Health and Education Quality Systems Strengthening, Freetown, Sierra Leone.
Sedzro KM; Department of Epidemiology, College of Health Sciences, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Kandeh J; Health and Education Quality Systems Strengthening, Freetown, Sierra Leone.
Tagoe H; John Snow Resarch & Training Institute Inc, Accra, Ghana.
Addo C; Department of Epidemiology, College of Health Sciences, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Arhinful DK; Department of Epidemiology, College of Health Sciences, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Sessay ARC; Department of Biostatistics, School of Public Health, College of Health Sciences, University of Ghana, Accra, Ghana.
Kamara JL; National HIV/AIDS Secretariat, Freetown, Sierra Leone.
Mansaray K; National HIV/AIDS Secretariat, Freetown, Sierra Leone.
Ampofo WK; Department of Virology, College of Health Sciences, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana.
Pokaż więcej
Źródło:
AIDS research and therapy [AIDS Res Ther] 2023 Sep 27; Vol. 20 (1), pp. 70. Date of Electronic Publication: 2023 Sep 27.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
HIV Infections*/diagnosis
HIV Infections*/epidemiology
HIV Infections*/drug therapy
Transgender Persons*
Sex Workers*
Sexual and Gender Minorities*
Substance Abuse, Intravenous*/epidemiology
Drug Users*
Male ; Humans ; Female ; Homosexuality, Male ; Sierra Leone/epidemiology ; Prevalence ; Prisons
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 1309

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies